Dumb Money Live

The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we'll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis.

Here are the GLP-1 RA drug makers and their drugs:

Eli Lilly (ticker LLY)

Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023.

Dulaglutide sold as Trulicity.

Novo Nordisk (ticker NVO)

Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss.

Liraglutide sold as Victoza for diabetes and Saxenda for weight loss.

Today's FTX bankruptcy filing reveals new information and we reveal the real reason we said "no" to SBF and FTX.

Today on Dumb Money, we're picking stocks that should benefit from an unusually cold winter. Bundle up!

Today on Dumb Money, how we are playing the crypto collapse.

We hate the company but kinda love the stock. Today on Dumb Money, we'll decide if we're investing before earnings.

Today on Dumb Money, we reveal TWO huge apparel trends and the ONE company we're investing in.

Today on Dumb Money, how we're preparing for the worst. We'll catch up on our latest stock plays and answer your questions.

We're back! Did we miss anything? Today on Dumb Money, it's a live chat happy hour edition.

Last week's #BamaRushTok featured a bunch of must-have brands for 2022. Today on Dumb Money, we're going shopping and revealing our STOCK PICKS that could get a boost from the TikTok hype.

Today on Dumb Money, why we think this stock could have a 40X return.